Brazilian guidelines for the treatment of outpatients with suspected or confirmed COVID-19. A joint guideline of the Brazilian Association of Emergency Medicine (ABRAMEDE), Brazilian Medical Association (AMB), Brazilian Society of Angiology and Vascular Surgery (SBACV), Brazilian Society of Geriatrics and Gerontology (SBGG), Brazilian Society of Infectious Diseases (SBI), Brazilian Society of Family and Community Medicine (SBFMC), and Brazilian Thoracic Society (SBPT)

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorFALAVIGNA, Maicon
dc.contributor.authorBELLI, Karlyse Claudino
dc.contributor.authorBARBOSA, Alexandre Naime
dc.contributor.authorZAVASCKI, Alexandre Prehn
dc.contributor.authorNASTRI, Ana Catharina de Seixas Santos
dc.contributor.authorSANTANA, Christiane Machado
dc.contributor.authorSTEIN, Cinara
dc.contributor.authorGRAF, Debora Dalmas
dc.contributor.authorCADEGIANI, Flavio Adsuara
dc.contributor.authorGUIMARAES, Helio Penna
dc.contributor.authorMONTEIRO, Jose Tadeu
dc.contributor.authorFERREIRA, Juliana Carvalho
dc.contributor.authorAZEVEDO, Luciano Cesar Pontes de
dc.contributor.authorMAGRI, Marcelo Mihailenko Chaves
dc.contributor.authorSOBREIRA, Marcone Lima
dc.contributor.authorDIAS, Maria Beatriz Gandra de Souza
dc.contributor.authorOLIVEIRA, Maura Salaroli de
dc.contributor.authorCORRADI, Mirian de Freitas Dal Ben
dc.contributor.authorROSA, Regis
dc.contributor.authorHEINZELMANN, Ricardo Souza
dc.contributor.authorSILVA, Rosemeri Maurici da
dc.contributor.authorBELFORT JUNIOR, Rubens
dc.contributor.authorCIMERMAN, Sergio
dc.contributor.authorCOLPANI, Veronica
dc.contributor.authorVEIGA, Viviane Cordeiro
dc.contributor.authorCARVALHO, Carlos Roberto Ribeiro de
dc.date.accessioned2022-08-12T17:05:51Z
dc.date.available2022-08-12T17:05:51Z
dc.date.issued2022
dc.description.abstractBackground: Several therapies have been used or proposed for the treatment of COVID-19, although their effectiveness and safety have not been properly evaluated. The purpose of this document is to provide recommendations to support decisions about the drug treatment of outpatients with COVID-19 in Brazil.Methods: A panel consisting of experts from different clinical fields, representatives of the Brazilian Ministry of Health, and methodologists (37 members in total) was responsible for preparing these guidelines. A rapid guideline development method was used, based on the adoption and/or adaptation of recommendations from existing international guidelines combined with additional structured searches for primary studies and new recommendations whenever necessary (GRADE-ADOLOPMENT). The rating of quality of evidence and the drafting of recommendations followed the GRADE method.Results: Ten technologies were evaluated, and 10 recommendations were prepared. Recommendations were made against the use of anticoagulants, azithromycin, budesonide, colchicine, corticosteroids, hydroxychloroquine/chloroquine alone or combined with azithromycin, ivermectin, nitazoxanide, and convalescent plasma. It was not possible to make a recommendation regarding the use of monoclonal antibodies in outpatients, as their benefit is uncertain and their cost is high, with limitations of availability and implementation.Conclusion: To date, few therapies have demonstrated effectiveness in the treatment of outpatients with COVID-19. Recommendations are restricted to what should not be used, in order to provide the best treatment according to the principles of evidence-based medicine and to promote resource savings by aboiding ineffective treatments. (c) 2022 Sociedade Brasileira de Infectologia.eng
dc.description.indexMEDLINEeng
dc.description.sponsorshipInstitutional Development Program of the Brazilian Unified Health System (PROADI-SUS)
dc.identifier.citationBRAZILIAN JOURNAL OF INFECTIOUS DISEASES, v.26, n.2, article ID 102347, 10p, 2022
dc.identifier.doi10.1016/j.bjid.2022.102347
dc.identifier.eissn1678-4391
dc.identifier.issn1413-8670
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/48348
dc.language.isoeng
dc.publisherELSEVIER BRAZILeng
dc.relation.ispartofBrazilian Journal of Infectious Diseases
dc.rightsopenAccesseng
dc.rights.holderCopyright ELSEVIER BRAZILeng
dc.subjectCOVID-19eng
dc.subjectCOVID-19 drug treatmenteng
dc.subjectGuidelineeng
dc.subjectSARS-CoV-2eng
dc.subjectBrazileng
dc.subjectGRADEeng
dc.subject.wosInfectious Diseaseseng
dc.titleBrazilian guidelines for the treatment of outpatients with suspected or confirmed COVID-19. A joint guideline of the Brazilian Association of Emergency Medicine (ABRAMEDE), Brazilian Medical Association (AMB), Brazilian Society of Angiology and Vascular Surgery (SBACV), Brazilian Society of Geriatrics and Gerontology (SBGG), Brazilian Society of Infectious Diseases (SBI), Brazilian Society of Family and Community Medicine (SBFMC), and Brazilian Thoracic Society (SBPT)eng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryCanadá
hcfmusp.affiliation.countryisoca
hcfmusp.author.externalFALAVIGNA, Maicon:Hosp Moinhos Vento, Rua Ramiro Barcelos 630-1015, BR-90035001 Porto Alegre, RS, Brazil; Univ Fed Rio Grande do Sul, Inst Avaliacao Tecnol Saude IATS, Porto Alegre, RS, Brazil; McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
hcfmusp.author.externalBELLI, Karlyse Claudino:Hosp Moinhos Vento, Rua Ramiro Barcelos 630-1015, BR-90035001 Porto Alegre, RS, Brazil
hcfmusp.author.externalBARBOSA, Alexandre Naime:Univ Estadual Paulista, Dept Infectol, Fac Med, Sao Paulo, Brazil
hcfmusp.author.externalZAVASCKI, Alexandre Prehn:Hosp Moinhos Vento, Serv Infectol & Controle Infeccao, Porto Alegre, RS, Brazil; Univ Fed Rio Grande do Sul, Dept Med Interna, Porto Alegre, RS, Brazil; Hosp Clin Porto Alegre, Serv Infectol, Porto Alegre, RS, Brazil
hcfmusp.author.externalSANTANA, Christiane Machado:Univ Fed Bahia UFBA, Salvador, BA, Brazil
hcfmusp.author.externalSTEIN, Cinara:Hosp Moinhos Vento, Rua Ramiro Barcelos 630-1015, BR-90035001 Porto Alegre, RS, Brazil
hcfmusp.author.externalGRAF, Debora Dalmas:Hosp Moinhos Vento, Rua Ramiro Barcelos 630-1015, BR-90035001 Porto Alegre, RS, Brazil
hcfmusp.author.externalCADEGIANI, Flavio Adsuara:Corpometria Inst, Brasilia, DF, Brazil
hcfmusp.author.externalGUIMARAES, Helio Penna:Escola Paulista Med UNIFESP EPM, Sao Paulo, Brazil
hcfmusp.author.externalMONTEIRO, Jose Tadeu:Univ Fed Para, Belem, Para, Brazil
hcfmusp.author.externalSOBREIRA, Marcone Lima:Univ Estadual Paulista, Hosp Clin Fac Med Botucatu HCFMB, Sao Paulo, Brazil
hcfmusp.author.externalCORRADI, Mirian de Freitas Dal Ben:Hosp Sirio Libanes, Sao Paulo, Brazil
hcfmusp.author.externalROSA, Regis:Hosp Moinhos Vento, Rua Ramiro Barcelos 630-1015, BR-90035001 Porto Alegre, RS, Brazil
hcfmusp.author.externalHEINZELMANN, Ricardo Souza:Univ Fed Santa Maria UFSM, Dept Saude Colet, Santa Maria, RS, Brazil; Hosp Univ Santa Maria, Serv Atencao Domiciliar, Santa Maria, RS, Brazil
hcfmusp.author.externalSILVA, Rosemeri Maurici da:Univ Fed Santa Catarina UFSC, Florianopolis, SC, Brazil
hcfmusp.author.externalBELFORT JUNIOR, Rubens:Univ Estadual Paulista, Hosp Clin Fac Med Botucatu HCFMB, Sao Paulo, Brazil
hcfmusp.author.externalCIMERMAN, Sergio:Inst Infectol Emilio Ribas, Sao Paulo, Brazil
hcfmusp.author.externalCOLPANI, Veronica:Hosp Moinhos Vento, Rua Ramiro Barcelos 630-1015, BR-90035001 Porto Alegre, RS, Brazil
hcfmusp.author.externalVEIGA, Viviane Cordeiro:Assoc Beneficencia Portuguesa Sao Paulo BP, Sao Paulo, Brazil
hcfmusp.citation.scopus3
hcfmusp.contributor.author-fmusphcANA CATHARINA DE SEIXAS SANTOS NASTRI
hcfmusp.contributor.author-fmusphcJULIANA CARVALHO FERREIRA
hcfmusp.contributor.author-fmusphcLUCIANO CESAR PONTES DE AZEVEDO
hcfmusp.contributor.author-fmusphcMARCELLO MIHAILENKO CHAVES MAGRI
hcfmusp.contributor.author-fmusphcMARIA BEATRIZ GANDRA DE SOUZA DIAS
hcfmusp.contributor.author-fmusphcMAURA SALAROLI DE OLIVEIRA
hcfmusp.contributor.author-fmusphcCARLOS ROBERTO RIBEIRO DE CARVALHO
hcfmusp.description.articlenumber102347
hcfmusp.description.issue2
hcfmusp.description.volume26
hcfmusp.origemWOS
hcfmusp.origem.pubmed35341739
hcfmusp.origem.scieloSCIELO:S1413-86702022000200201
hcfmusp.origem.scopus2-s2.0-85127469982
hcfmusp.origem.wosWOS:000805171900001
hcfmusp.publisher.cityRIO DE JANEIROeng
hcfmusp.publisher.countryBRAZILeng
hcfmusp.relation.referenceAkl EA, 2021, J CLIN EPIDEMIOL, V129, P1, DOI 10.1016/j.jclinepi.2020.09.037eng
hcfmusp.relation.referenceamb, DIRETRIZES COVID 19eng
hcfmusp.relation.reference[Anonymous], 2022, WEEKLY EPIDEMIOLOGICeng
hcfmusp.relation.reference[Anonymous], 2022, PAINEL CORONAVRUSeng
hcfmusp.relation.referenceastrazeneca, AZD7442 PROVENT PHASeng
hcfmusp.relation.referenceAzoulay E, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03194-weng
hcfmusp.relation.referenceBernal AJ, 2022, NEW ENGL J MED, V386, P509, DOI 10.1056/NEJMoa2116044eng
hcfmusp.relation.referenceBerwanger O, 2022, LANCET GLOB HEALTH, V10, pE2, DOI 10.1016/S2214-109X(21)00501-5eng
hcfmusp.relation.referenceBhimraj A, IDSA GUIDELINES TREAeng
hcfmusp.relation.referenceBhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478eng
hcfmusp.relation.referenceBrazilian Clinical Research Institute, AP PROPHYLAXIS THROMeng
hcfmusp.relation.referenceChalmers JD, 2021, EUR RESPIR J, V57, DOI 10.1183/13993003.00048-2021eng
hcfmusp.relation.referenceconitec, DIRETRIZES BRASILEIReng
hcfmusp.relation.referencecovid19evidence, NATL COVID 19 CLIN Eeng
hcfmusp.relation.referenceFalavigna Maicon, 2020, Rev. bras. ter. intensiva, V32, P166, DOI 10.5935/0103-507x.20200039eng
hcfmusp.relation.referenceGuimaraes PO, 2021, NEW ENGL J MED, V385, P406, DOI 10.1056/NEJMoa2101643eng
hcfmusp.relation.referenceGuyatt G, 2011, J CLIN EPIDEMIOL, V64, P383, DOI 10.1016/j.jclinepi.2010.04.026eng
hcfmusp.relation.referencehcor, COALIZAO COVID BRASIeng
hcfmusp.relation.referenceJanssen Research & Development LLC, 2021, STUD RIV RED RISK MAeng
hcfmusp.relation.referenceKalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742eng
hcfmusp.relation.referenceKlimek L, 2021, HNO, V69, P35, DOI 10.1007/s00106-021-01070-9eng
hcfmusp.relation.referenceLee K, 2009, GLOB INST, P1eng
hcfmusp.relation.referenceLotfi T, 2021, J CLIN EPIDEMIOL, V135, P182, DOI 10.1016/j.jclinepi.2021.03.034eng
hcfmusp.relation.referenceMarconi VC, 2021, LANCET RESP MED, V9, P1407, DOI 10.1016/S2213-2600(21)00331-3eng
hcfmusp.relation.referenceMerck, INT AN 7 3 PERC PATeng
hcfmusp.relation.referenceNIH, COVID 19 TREATM GUIDeng
hcfmusp.relation.referencepfizer.com, PFIZ NOV COVID 19 OReng
hcfmusp.relation.referenceRecovery trial, USeng
hcfmusp.relation.referenceReis G, 2022, LANCET GLOB HEALTH, V10, pE36, DOI 10.1016/S2214-109X(21)00448-4eng
hcfmusp.relation.referenceSchunemann HJ, 2014, CAN MED ASSOC J, V186, pE123, DOI 10.1503/cmaj.131237eng
hcfmusp.relation.referenceSchunemann H, GRADE HDB HDB GRADINeng
hcfmusp.relation.referenceSchunemann HJ, 2017, J CLIN EPIDEMIOL, V81, P101, DOI 10.1016/j.jclinepi.2016.09.009eng
hcfmusp.relation.referenceSciurba Frank C., 2021, COVID 19 POSITIVE OUeng
hcfmusp.relation.referenceTanni SEB HA, 2021, WORLD MED J, V2, P37eng
hcfmusp.relation.referenceThe National Institute for Health and Care Excellence (NICE) London, COVID 19 RAP GUID MAeng
hcfmusp.relation.referencetogethertrial, TOGHETER CLIN TRIALSeng
hcfmusp.relation.referencewho, WHO COVID 19 SOLIDAReng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication177403b6-b941-4ca0-bf8e-205e036686d2
relation.isAuthorOfPublicationd9ff0200-05aa-44bb-b4ec-35039188d680
relation.isAuthorOfPublicationccc3fdb0-6f9d-468e-9027-9d0671b66151
relation.isAuthorOfPublicationd659102b-c47c-42a8-a6cb-9f0de5c3fbba
relation.isAuthorOfPublicationbe10e987-9df9-4c8c-9217-6e0f86552a12
relation.isAuthorOfPublication523fbddd-0b6e-41e8-ada1-fbf28c039496
relation.isAuthorOfPublicationf1b24304-c10c-4be9-95d8-010b78bf2a73
relation.isAuthorOfPublication.latestForDiscoverybe10e987-9df9-4c8c-9217-6e0f86552a12
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_FALAVIGNA_Brazilian_guidelines_for_the_treatment_of_outpatients_with_2022.PDF
Tamanho:
529.74 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/09
Artigos e Materiais de Revistas Científicas - LIM/48
Carregar mais